Source link : https://www.newshealth.biz/health-news/long-term-data-support-efficacy-safety-of-new-schizophrenia-drug/
Recently approved xanomeline and trospium chloride (Cobenfy) demonstrated long-term efficacy and safety in patients with schizophrenia, long-term results from the phase III EMERGENT-4 trial showed. Participants who continued taking the drug after the initial 5-week treatment period of two prior trials had a durable improvement in their Positive and Negative Syndrome Scale (PANSS) total score, […]
Author : News Health
Publish date : 2024-11-06 19:24:13
Copyright for syndicated content belongs to the linked Source.
